On June 3, Innovent Biologics fell 3.04% in regular trading, trading at HKD 76.45/share, with trading volume of HKD 242 million. The stock has declined for multiple consecutive sessions after surging over 11% on May 29 following the announcement of a $10.5 billion global strategic collaboration with Pfizer.

On the news front, market concerns persist over whether the transaction can secure regulatory approval. Recent discussions surrounding potential revisions to biomedical export control lists and the U.S. COINS Act, which may impose restrictions on cross-border biotech collaborations, have intensified uncertainty and suppressed investor sentiment.

Meanwhile, the broader biotech sector continued its weak performance, with AKESO down 4.04%, REMEGEN down 4.04%, 3SBIO down 3.38%, EVEREST MED down 2.69%, and BEIGENE down 2.67%, creating systematic selling pressure that further weighed on Innovent Biologics through sector-wide contagion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)